MX2021002916A - Pirfenidona enriquecida con deuterio y métodos para su uso. - Google Patents

Pirfenidona enriquecida con deuterio y métodos para su uso.

Info

Publication number
MX2021002916A
MX2021002916A MX2021002916A MX2021002916A MX2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A MX 2021002916 A MX2021002916 A MX 2021002916A
Authority
MX
Mexico
Prior art keywords
methods
deuterium
enriched pirfenidone
enriched
compounds
Prior art date
Application number
MX2021002916A
Other languages
English (en)
Inventor
Eric Elenko
Michael C Chen
Luann Sabounjian
Original Assignee
Puretech Lyt 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt 100 Inc filed Critical Puretech Lyt 100 Inc
Publication of MX2021002916A publication Critical patent/MX2021002916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

En el presente documento se describen compuestos de N-aril piridinona enriquecida con deuterio, opcionalmente en combinación con uno o más agentes terapéuticos adicionales, las composiciones farmacéuticas que los comprenden, los métodos para su preparación y los métodos para su uso. Tales compuestos y composiciones son útiles, por ejemplo, en el tratamiento de enfermedades, trastornos o afecciones como el edema.
MX2021002916A 2018-09-14 2019-09-16 Pirfenidona enriquecida con deuterio y métodos para su uso. MX2021002916A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731570P 2018-09-14 2018-09-14
US201862750377P 2018-10-25 2018-10-25
US201962839256P 2019-04-26 2019-04-26
US201962884984P 2019-08-09 2019-08-09
PCT/US2019/051369 WO2020056430A1 (en) 2018-09-14 2019-09-16 Deuterium-enriched pirfenidone and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021002916A true MX2021002916A (es) 2021-08-24

Family

ID=68073243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002916A MX2021002916A (es) 2018-09-14 2019-09-16 Pirfenidona enriquecida con deuterio y métodos para su uso.

Country Status (11)

Country Link
US (2) US20200093810A1 (es)
EP (1) EP3849551A1 (es)
JP (1) JP2022501427A (es)
KR (1) KR20210076000A (es)
CN (1) CN112996508A (es)
AU (1) AU2019339536A1 (es)
CA (1) CA3112765A1 (es)
IL (1) IL281420A (es)
MX (1) MX2021002916A (es)
SG (1) SG11202102581YA (es)
WO (1) WO2020056430A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CA3175866A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
WO2022010925A1 (en) * 2020-07-06 2022-01-13 Puretech Lyt 100, Inc. Methods of treating diseases and disorders with deupirfenidone
EP4333853A1 (en) * 2021-05-03 2024-03-13 Thirona Bio, Inc. Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
WO2023133476A1 (en) * 2022-01-05 2023-07-13 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CN115337315A (zh) * 2022-07-13 2022-11-15 陕西慧康生物科技有限责任公司 三氮脒在制备治疗肝纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
WO2003014087A1 (fr) 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
CN103561741A (zh) 2011-03-08 2014-02-05 奥斯拜客斯制药有限公司 取代的n-芳基吡啶酮
WO2014134132A1 (en) 2013-02-26 2014-09-04 University Of Louisville Research Foundation, Inc. Milk-derived microvesicle compositions and related methods
EP3096758A1 (en) 2014-01-24 2016-11-30 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
AU2016215173B2 (en) * 2015-02-05 2019-11-21 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Also Published As

Publication number Publication date
CA3112765A1 (en) 2020-03-19
JP2022501427A (ja) 2022-01-06
US20200093810A1 (en) 2020-03-26
AU2019339536A1 (en) 2021-04-29
US20210205283A1 (en) 2021-07-08
CN112996508A (zh) 2021-06-18
EP3849551A1 (en) 2021-07-21
IL281420A (en) 2021-04-29
SG11202102581YA (en) 2021-04-29
WO2020056430A1 (en) 2020-03-19
KR20210076000A (ko) 2021-06-23

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021009673A (es) Moduladores de ror-gamma.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
AU2022206685B2 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12021550872A1 (en) Therapeutic compounds
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MY201535A (en) Therapeutic compounds
MX2022000712A (es) Moduladores de nlrp3.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12017501668A1 (en) Bace1 inhibitors
MX2021008941A (es) Moduladores gpr35.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.